Lacosamide Zentiva (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilizing hyper‑excitable cells and preventing the rapid repetitive firing that underlies seizure activity. This selective modulation reduces seizure propagation without significantly affecting normal neuronal signaling.

The appropriate dose of Lacosamide Zentiva is determined by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for lacosamide in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents and may result in a distinct side‑effect profile, especially regarding cardiac conduction effects.

Lacosamide Zentiva tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Lacosamide Zentiva is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and rare cases of suicidal thoughts or behavior. Patients should be monitored for these events, especially during treatment initiation or dose changes.

Lacosamide is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is also advised for individuals with pre‑existing cardiac conduction disorders, severe renal or hepatic impairment, and those taking other sodium‑channel‑blocking agents without appropriate monitoring.